Matches in SemOpenAlex for { <https://semopenalex.org/work/W1859724961> ?p ?o ?g. }
- W1859724961 endingPage "1149" @default.
- W1859724961 startingPage "1137" @default.
- W1859724961 abstract "To evaluate the benefit of adjuvant chemotherapy in adult patients with soft tissue sarcomas. The principal end points were freedom from local recurrence and/or metastases and overall survival.Between January 1977 and June 1988, 468 patients entered this randomized study and 317 were considered eligible. Following complete surgical resection with or without radiotherapy, outcome in 145 eligible patients receiving cyclophosphamide 500 mg/m2 intravenously (IV) bolus on day 1, vincristine 1.4 mg/m2 IV bolus on day 1, doxorubicin (Adriamycin; Adria Laboratories, Columbus, OH) 50 mg/m2 IV bolus on day 1, and dacarbazine (DTIC) 400 mg/m2 by 1-hour infusion on days 1 to 3 (CYVADIC) cycles repeated every 28 days for eight courses was compared with that in 172 control patients.With a median follow-up duration of 80 months (range, 39 to 165), actuarial percentage survival figures at 7 years were compared. Relapse-free survival rates were higher for CYVADIC, 56% versus 43% (P = .007), and local recurrence was significantly reduced in the CYVADIC arm at 17% versus 31% (P = .004). In contrast, distant metastases occurred with similar frequency in both arms, 32% for CYVADIC versus 36% for control patients (P = .42), and overall survival rates were not significantly different at 63% versus 56% (P = .64). A reduction in local recurrence was only apparent in the group of head, neck, and trunk sarcomas (P = .002), but not in limb tumors (P = .31).Adjuvant chemotherapy with CYVADIC cannot be recommended outside the context of a clinical trial. Experience from this study has been used to plan a trial of neoadjuvant chemotherapy with doxorubicin/ifosfamide, which is currently in progress." @default.
- W1859724961 created "2016-06-24" @default.
- W1859724961 creator A5009031374 @default.
- W1859724961 creator A5019248098 @default.
- W1859724961 creator A5042582850 @default.
- W1859724961 creator A5044522532 @default.
- W1859724961 creator A5052460181 @default.
- W1859724961 creator A5068719359 @default.
- W1859724961 creator A5068869646 @default.
- W1859724961 creator A5079005567 @default.
- W1859724961 creator A5082045927 @default.
- W1859724961 creator A5087576978 @default.
- W1859724961 date "1994-06-01" @default.
- W1859724961 modified "2023-10-09" @default.
- W1859724961 title "Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma--reduced local recurrence but no improvement in survival: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group." @default.
- W1859724961 cites W1851896728 @default.
- W1859724961 cites W1928072155 @default.
- W1859724961 cites W1944507750 @default.
- W1859724961 cites W1974093039 @default.
- W1859724961 cites W1986666007 @default.
- W1859724961 cites W2013313438 @default.
- W1859724961 cites W2019103457 @default.
- W1859724961 cites W2038448746 @default.
- W1859724961 cites W2038586922 @default.
- W1859724961 cites W2055063099 @default.
- W1859724961 cites W2082065626 @default.
- W1859724961 cites W2084641922 @default.
- W1859724961 cites W2084869046 @default.
- W1859724961 cites W2094626701 @default.
- W1859724961 cites W2114081348 @default.
- W1859724961 cites W2125819884 @default.
- W1859724961 cites W2126540415 @default.
- W1859724961 cites W2145535642 @default.
- W1859724961 cites W2247969479 @default.
- W1859724961 cites W2265301974 @default.
- W1859724961 cites W2312350918 @default.
- W1859724961 cites W2412562601 @default.
- W1859724961 cites W2427524427 @default.
- W1859724961 cites W2469614249 @default.
- W1859724961 cites W2470476586 @default.
- W1859724961 cites W2569020266 @default.
- W1859724961 cites W3023209649 @default.
- W1859724961 cites W3553373 @default.
- W1859724961 cites W79296334 @default.
- W1859724961 cites W95089460 @default.
- W1859724961 cites W2617264488 @default.
- W1859724961 doi "https://doi.org/10.1200/jco.1994.12.6.1137" @default.
- W1859724961 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8201375" @default.
- W1859724961 hasPublicationYear "1994" @default.
- W1859724961 type Work @default.
- W1859724961 sameAs 1859724961 @default.
- W1859724961 citedByCount "226" @default.
- W1859724961 countsByYear W18597249612012 @default.
- W1859724961 countsByYear W18597249612013 @default.
- W1859724961 countsByYear W18597249612014 @default.
- W1859724961 countsByYear W18597249612015 @default.
- W1859724961 countsByYear W18597249612016 @default.
- W1859724961 countsByYear W18597249612017 @default.
- W1859724961 countsByYear W18597249612018 @default.
- W1859724961 countsByYear W18597249612019 @default.
- W1859724961 countsByYear W18597249612020 @default.
- W1859724961 countsByYear W18597249612021 @default.
- W1859724961 countsByYear W18597249612022 @default.
- W1859724961 countsByYear W18597249612023 @default.
- W1859724961 crossrefType "journal-article" @default.
- W1859724961 hasAuthorship W1859724961A5009031374 @default.
- W1859724961 hasAuthorship W1859724961A5019248098 @default.
- W1859724961 hasAuthorship W1859724961A5042582850 @default.
- W1859724961 hasAuthorship W1859724961A5044522532 @default.
- W1859724961 hasAuthorship W1859724961A5052460181 @default.
- W1859724961 hasAuthorship W1859724961A5068719359 @default.
- W1859724961 hasAuthorship W1859724961A5068869646 @default.
- W1859724961 hasAuthorship W1859724961A5079005567 @default.
- W1859724961 hasAuthorship W1859724961A5082045927 @default.
- W1859724961 hasAuthorship W1859724961A5087576978 @default.
- W1859724961 hasConcept C126322002 @default.
- W1859724961 hasConcept C136948725 @default.
- W1859724961 hasConcept C141071460 @default.
- W1859724961 hasConcept C142724271 @default.
- W1859724961 hasConcept C151730666 @default.
- W1859724961 hasConcept C2776694085 @default.
- W1859724961 hasConcept C2776755627 @default.
- W1859724961 hasConcept C2778256501 @default.
- W1859724961 hasConcept C2778629024 @default.
- W1859724961 hasConcept C2779343474 @default.
- W1859724961 hasConcept C2779429289 @default.
- W1859724961 hasConcept C2780964509 @default.
- W1859724961 hasConcept C43376680 @default.
- W1859724961 hasConcept C509974204 @default.
- W1859724961 hasConcept C71924100 @default.
- W1859724961 hasConcept C86803240 @default.
- W1859724961 hasConceptScore W1859724961C126322002 @default.
- W1859724961 hasConceptScore W1859724961C136948725 @default.
- W1859724961 hasConceptScore W1859724961C141071460 @default.
- W1859724961 hasConceptScore W1859724961C142724271 @default.
- W1859724961 hasConceptScore W1859724961C151730666 @default.
- W1859724961 hasConceptScore W1859724961C2776694085 @default.
- W1859724961 hasConceptScore W1859724961C2776755627 @default.